


This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:


1-21. (canceled)

22. (currently amended) A process for preparing an oligonucleotide having the formula:



wherein:


R₁ is a group having the formula:



Q₀ is O or S;

R₄ is O⁻, hydroxyl, or a protected hydroxyl;

R₂ is hydroxyl, a protected hydroxyl or a group having the formula:



each R_3 is H, a 2'-substituent group or a protected 2'-substituent group;

each X is, independently, O^- , hydroxyl, protected hydroxyl, or $-\text{S}-\text{L}_3$;

each Bx is an optionally protected heterocyclic base moiety;


n is from 3 to about 50; and

L_1 , L_2 and each of said L_3 are, independently, a cholesterol, phospholipid, biotin, phenazine, phenanthridine, anthraquinone, acridine, fluorescein, rhodamine, coumarin, or dye;

wherein said R_1 and at least one of said R_2 or said X comprise a cholesterol, phospholipid, biotin, phenazine, phenanthridine, anthraquinone, acridine, fluorescein, rhodamine, or coumarin, or dye;

comprising the steps of:

a) providing a derivatized solid support for oligonucleotide synthesis, said derivatized solid support being derivatized with a group having one of the structures:




wherein

T is a bifunctional linking moiety linked to the solid support; and

Q_1 is an acid labile hydroxyl protecting group;

b) treating said derivatized solid support with an acidic reagent to deblock said acid labile hydroxyl protecting group to give a free hydroxyl group;

c) reacting said free hydroxyl group with a phosphoramidite composition to form an extended compound, said phosphoramidite composition having the formula:



wherein

Q₂ is a 5'-terminal acid labile hydroxyl protecting group;

Q₃ is a phosphorus protecting group; and


Z₆ and Z₇ are, independently, C₁₋₆ alkyl;

or Z₆ and Z₇ are joined together to form a 4- to 7-membered heterocyclic ring system including the nitrogen atom to which Z₆ and Z₇ are attached, wherein said ring system optionally includes at least one additional heteroatom selected from O, N and S;

d) oxidizing said extended compound to form an oxidized compound, or treating said extended compound with an acidic reagent to deblock said 5'-terminal acid labile hydroxyl protecting group of said extended compound to give a free hydroxyl group and repeating step c) at least one time followed by oxidizing said extended compound to form an oxidized compound;

e) treating said oxidized compound with an acidic reagent to deblock said acid labile hydroxyl protecting group to give a free hydroxyl group and repeating steps c) and d) at least three times to form an extended oxidized compound;

f) treating said extended oxidized compound with a reagent effective to deblock said protected hydroxyl group to give a free hydroxyl group and reacting said free hydroxyl group with a compound of formula:



thereby forming a 5'-functionalized compound;

wherein


Q₅ is an acid labile hydroxyl protecting group;

g) treating said 5'-functionalized compound for a time and under conditions effective to remove at least one phosphorus protecting group giving at least one deblocked phosphorothioate linkage; and

h) reacting said deblocked phosphorothioate linkage with a cholesterol, phospholipid, biotin, phenazine, phenanthridine, anthraquinone, acridine, fluorescein, rhodamine, or coumarin, ~~or~~ dye that is reactive with and forms a covalent bond with said deblocked phosphorothioate linkage to give said oligonucleotide.

23. (original) The process of Claim 22 further comprising the step of treating said 5'-functionalized compound with a capping agent to form a capped compound.

24. (original) The process of Claim 22 wherein said R₂ is a group having the formula:



25. (original) The process of Claim 24 wherein L₁ is different from L₂.

26. (original) The process of Claim 22 wherein at least one of said X is -S-L₃.
27. (original) The process of Claim 26 wherein L₁ is different from L₃.
28. (canceled)
29. (canceled)
30. (previously presented) The process of Claim 22 wherein each of said Q₃ is independently selected from the group consisting of cyanoethyl, diphenylsilylethyl, cyanobutenyl, cyano *p*-xylyl (CPX), methyl-N-trifluoroacetyl ethyl (META) and acetoxo phenoxy ethyl (APOE) groups.
31. (original) The process of Claim 22 wherein said 5'-functionalized compound is treated in step g) to remove all phosphorus protecting groups.
32. (original) The process of Claim 22 wherein n is from about 8 to about 30.
33. (original) The process of Claim 32 wherein n is from about 15 to about 25.
34. (original) The process of Claim 22 wherein each of said Q₁ and Q₂ is independently selected from the group consisting of trimethoxytrityl, dimethoxytrityl (DMT), monomethoxytrityl, 9-phenylxanthen-9-yl (Pixyl) and 9-(*p*-methoxyphenyl)xanthen-9-yl (Mox).
35. (original) The process of Claim 22 wherein each of said Bx is independently selected from the group consisting of adenine, guanine, thymine, cytosine, uracil, 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine, 2-thiocytosine, 5-halouracil, 5-halocytosine, 5-propynyl uracil, 5-propynyl cytosine, 6-azo uracil, 6-azo cytosine, 6-azo

thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-substituted adenines and guanines, 5-substituted uracils and cytosines, 7-methylguanine, 7-methyladenine, 8-azaguanine, 8-azaadenine, 7-deazaguanine, 7-deazaadenine, 3-deazaguanine and 3-deazaadenine.


36. (original) The process of Claim 22 wherein at least one of said L_1 , L_2 , and L_3 is attached to the oligonucleotide through a linking group.

37. (original) The process of Claim 36 wherein the linking group comprises a dialkylglycerol linker.

38. (original) The process of Claim 22 wherein each of said Z_6 and Z_7 is isopropyl.

39. (original) The process of Claim 22 wherein each R_3 is, independently, C_1 - C_{20} alkyl, C_2 - C_{20} alkenyl, C_2 - C_{20} alkynyl, C_5 - C_{20} aryl, O-alkyl, O-alkenyl, O-alkynyl, O-alkylamino, O-alkylalkoxy, O-alkylaminoalkyl, O-alkyl imidazole, thiol, S-alkyl, S-alkenyl, S-alkynyl, NH-alkyl, NH-alkenyl, NH-alkynyl, N-dialkyl, O-aryl, S-aryl, NH-aryl, O-aralkyl, S-aralkyl, NH-aralkyl, N-phthalimido, halogen keto, carboxyl, nitro, nitroso, nitrile, trifluoromethyl, trifluoromethoxy, imidazole, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide, disulfide, silyl, heterocycle, carbocycle, polyamine, polyamide, polyalkylene glycol, and polyether;

or each substituent group has one of formula I or II:




wherein:

Z_0 is O, S or NH;

J is a single bond, O or C(=O);

E is C_1 - C_{10} alkyl, $N(R_5)(R_6)$, $N(R_5)(R_7)$, $N=C(R_5)(R_6)$, $N=C(R_5)(R_7)$ or has one of formula III or IV;



each R_8 , R_9 , R_{10} , R_{11} and R_{12} is, independently, hydrogen, $C(O)R_{13}$, substituted or unsubstituted C_1 - C_{10} alkyl, substituted or unsubstituted C_2 - C_{10} alkenyl, substituted or unsubstituted C_2 - C_{10} alkynyl, alkylsulfonyl, arylsulfonyl, a chemical functional group or a conjugate group, wherein the substituent groups are selected from hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl, nitro, thiol, thioalkoxy, halogen, alkyl, aryl, alkenyl and alkynyl;

or optionally, R_9 and R_{10} , together form a phthalimido moiety with the nitrogen atom to which they are attached;

or optionally, R_{11} and R_{12} , together form a phthalimido moiety with the nitrogen atom to which they are attached;

each R_{13} is, independently, substituted or unsubstituted C_1 - C_{10} alkyl, trifluoromethyl, cyanoethoxy, methoxy, ethoxy, t-butoxy, allyloxy, 9-fluorenylmethoxy, 2-(trimethylsilyl)-ethoxy, 2,2,2-trichloroethoxy, benzyloxy, butyryl, iso-butyryl, phenyl or aryl;

R_5 is T-L,

T is a bond or a linking moiety;

L is a chemical functional group, a conjugate group or a solid support material;

each R_5 and R_6 is, independently, H, a nitrogen protecting group, substituted or unsubstituted C_1 - C_{10} alkyl, substituted or unsubstituted C_2 - C_{10} alkenyl, substituted or

unsubstituted C₂-C₁₀ alkynyl, wherein said substitution is OR₃, SR₃, NH₃⁺, N(R₁₄)(R₁₅), guanidino or acyl where said acyl is an acid amide or an ester;

or R₅ and R₆, together, are a nitrogen protecting group or are joined in a ring structure that optionally includes an additional heteroatom selected from N and O;

or R₂₁, T and L, together, are a chemical functional group;

each R₁₄ and R₁₅ is, independently, H, C₁-C₁₀ alkyl, a nitrogen protecting group, or R₁₄ and R₁₅, together, are a nitrogen protecting group;

or R₁₄ and R₁₅ are joined in a ring structure that optionally includes an additional heteroatom selected from N and O;

Z₄ is OX, SX, or N(X)₂;

each X is, independently, H, C₁-C₈ alkyl, C₁-C₈ haloalkyl, C(=NH)N(H)R₁₆, C(=O)N(H)R₁₆ or OC(=O)N(H)R₁₆;

R₁₆ is H or C₁-C₈ alkyl;

Z₁, Z₂ and Z₃ comprise a ring system having from about 4 to about 7 carbon atoms or having from about 3 to about 6 carbon atoms and 1 or 2 heteroatoms wherein said heteroatoms are selected from oxygen, nitrogen and sulfur and wherein said ring system is aliphatic, unsaturated aliphatic, aromatic, or saturated or unsaturated heterocyclic;

Z₅ is alkyl or haloalkyl having 1 to about 10 carbon atoms, alkenyl having 2 to about 10 carbon atoms, alkynyl having 2 to about 10 carbon atoms, aryl having 6 to about 14 carbon atoms, N(R₅)(R₆) OR₅, halo, SR₅ or CN;

each q₁ is, independently, an integer from 1 to 10;

each q₂ is, independently, 0 or 1;

q₃ is 0 or an integer from 1 to 10;


q₄ is an integer from 1 to 10;

q₅ is from 0, 1 or 2; and

provided that when q₃ is 0, q₄ is greater than 1.


40-49. (canceled)

50. (currently amended) A process for preparing an oligonucleotide having the formula:



wherein:


R₁ is a group having the formula:



Q₀ is O or S;

R₄ is O⁻, hydroxyl, or a protected hydroxyl;

R₂ is hydroxyl, a protected hydroxyl or a group having the formula:



each R₃ is H, a 2'-substituent group or a protected 2'-substituent group;

each X is, independently, O⁻, hydroxyl, a protected hydroxyl, or -S-L₃;


each Bx is an optionally protected heterocyclic base moiety;

n is from 3 to about 50; and

L_1 , L_2 and each of said L_3 are, independently, a cholesterol, phospholipid, biotin, phenazine, phenanthridine, anthraquinone, acridine, fluorescein, rhodamine, or coumarin, or dye;

comprising the steps of:

a) providing a derivatized solid support for oligonucleotide synthesis, said derivatized solid support being derivatized with a group having one of the structures:




wherein

T is a bifunctional linking moiety linked to the solid support; and

Q_1 is an acid labile hydroxyl protecting group;

b) treating said derivatized solid support with an acidic reagent to deblock said acid labile hydroxyl protecting group to give a free hydroxyl group;

c) reacting said free hydroxyl group with a phosphoramidite composition to form an extended compound, said phosphoramidite composition having the formula:



wherein

Q_2 is a 5'-terminal acid labile hydroxyl protecting group;

Q_3 is a phosphorus protecting group; and


Z_6 and Z_7 are, independently, C_{1-6} alkyl;

or Z_6 and Z_7 are joined together to form a 4- to 7-membered heterocyclic ring system including the nitrogen atom to which Z_6 and Z_7 are attached, wherein said ring system optionally includes at least one additional heteroatom selected from O, N and S;

d) oxidizing said extended compound to form an oxidized compound, or treating said extended compound with an acidic reagent to deblock said 5'-terminal acid labile hydroxyl protecting group of said extended compound to give a free hydroxyl group and repeating step c) at least one time followed by oxidizing said extended compound to form an oxidized compound;

e) treating said oxidized compound with an acidic reagent to deblock said acid labile hydroxyl protecting group to give a free hydroxyl group and repeating steps c) and d) at least three times to form an extended oxidized compound;

f) treating said extended oxidized compound with an acidic reagent effective to deblock said 5'-terminal acid labile hydroxyl protecting group to give a free hydroxyl group and reacting said free hydroxyl group with a compound of the formula:



thereby forming a 5'-functionalized compound;

wherein

Q_5 is an acid labile hydroxyl protecting group;

51. (original) The process of Claim 50 further comprising the step of treating said 5'-functionalized compound with a capping agent to form a capped compound.

52. (original) The process of Claim 50 wherein at least one of said L₁, L₂, and L₃ is attached to the oligonucleotide through a linking group.

53. (original) The process of Claim 52 wherein the linking group comprises a dialkylglycerol linker.

54. (original) The process of Claim 50 wherein each of said Z₆ and Z₇ is isopropyl.

55. (canceled)

56. (canceled)

57. (original) The process of Claim 50 wherein L₁ is different from L₂ and L₃.

58. (original) The process of Claim 50 wherein each of said Q₃ is independently selected from the group consisting of cyanoethyl, diphenylsilylethyl, cyanobutenyl, cyano *p*-xylyl (CPX), methyl-N-trifluoroacetyl ethyl (META) and acetoxo phenoxy ethyl (APOE) groups.

59. (original) The process of Claim 50 wherein each of said Q₁ and Q₂ is independently selected from the group consisting of trimethoxytrityl, dimethoxytrityl (DMT), monomethoxytrityl, 9-phenylxanthen-9-yl (Pixyl) and 9-(*p*-methoxyphenyl)xanthen-9-yl (Mox).

60. (original) The process of Claim 50 wherein each of said B_x is independently selected from the group consisting of adenine, guanine, thymine, cytosine, uracil, 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine, 2-thiocytosine, 5-halouracil, 5-halocytosine, 5-propynyl uracil, 5-propynyl cytosine, 6-azo uracil, 6-azo cytosine, 6-azo thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-substituted adenines and guanines, 5-

DOCKET NO.: ISIS-4723

PATENT

Application No.: 09/823,031

Office Action Dated: November 12, 2003

substituted uracils and cytosines, 7-methylguanine, 7-methyladenine, 8-azaguanine, 8-azaadenine, 7-deazaguanine, 7-deazaadenine, 3-deazaguanine and 3-deazaadenine.